Preferred Label : Anti-c-Met/MMAE ADC MYTX-011;
NCIt synonyms : Anti-c-Met ADC MYTX-011; ADC MYTX-011; Anti-c-Met-vcMMAE Antibody-drug Conjugate MYTX-011;
NCIt definition : An antibody-drug conjugate (ADC) composed of an engineered pH-dependent humanized
immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen
(TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) and conjugated,
via a valine-citrulline (VC) peptide linker, to monomethyl auristatin E (MMAE), an
auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic
activity. Upon intravenous administration of anti-c-Met/MMAE ADC MYTX-011, the monoclonal
antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding,
internalization, and proteolytic cleavage, MMAE is released. MMAE binds to tubulin
and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
This induces cell death in c-Met-expressing cancer cells. c-Met, a receptor tyrosine
kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor
cell proliferation, survival, invasion, metastasis and tumor angiogenesis. The engineered
pH-dependent anti-c-Met antibody allows enhanced binding and thus uptake into c-Met-expressing
cancer cells while reducing binding to and uptake in healthy cells. This may increase
efficacy and improve tolerability.;
Molecule name : MYTX 011; MYTX-011;
NCI Metathesaurus CUI : CL1906197;
Origin ID : C199255;
concept_is_in_subset
- has_target
